Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;18(2):179-181.
doi: 10.14802/jmd.24247. Epub 2025 Jan 6.

Levodopa Pharmacokinetics in Switching From Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in a Patient With Parkinson's Disease: A Case Report

Tomonori Nukariya  1   2   3 , Toshiki Tezuka  1   2   3 , Shohei Okusa  1   2   3 , Ryotaro Okochi  1   2   3 , Yuto Sakai  1   2   3 , Yoshihiro Nihei  1   2   3 , Jin Nakahara  1   2   3 , Morinobu Seki  1   2   3
Affiliations

Levodopa Pharmacokinetics in Switching From Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in a Patient With Parkinson's Disease: A Case Report

Tomonori Nukariya et al. J Mov Disord. 2025 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

The authors have no financial conflicts of interest.

Figures

Figure 1.
Figure 1.
The LD plasma concentration–time profiles of the patient whose case is presented here. A: During the LCT. According to the LD challenge protocol [7], the LD dose used in the LCT was 150 mg (her usual morning oral LD dose; 100 mg). B: Following the initiation of LCIG without a morning dose. C: After the initiation of CSCI. Four hours after the start of CSCI, the infusion rate was reduced from 0.37 mL/h to 0.34 mL/h because the patient’s dyskinesia became more severe. LD, levodopa; LCT, LD challenge test; LCIG, levodopa/carbidopa intestinal gel; CSCI, continuous subcutaneous infusion.
See this image and copyright information in PMC

References

    1. Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol. 2021;20:385–397. - PMC - PubMed
    1. Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020;323:548–560. - PubMed
    1. Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F, et al. Continuous subcutaneous foslevodopa/foscarbidopa in Parkinson’s disease: safety and efficacy results from a 12-month, single-arm, openlabel, phase 3 study. Neurol Ther. 2023;12:1937–1958. - PMC - PubMed
    1. Fung VSC, Aldred J, Arroyo MP, Bergquist F, Boon AJW, Bouchard M, et al. Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s disease: considerations for initiation and maintenance. Clin Park Relat Disord. 2024;10:100239. - PMC - PubMed
    1. Tezuka T, Nukariya T, Kizuka Y, Okusa S, Okochi R, Sakai Y, et al. Potential psychosis induced by a sustained high plasma levodopa concentration due to continuous subcutaneous foslevodopa/foscarbidopa infusion in a patient with Parkinson’s disease: a case report. J Mov Disord. 2024;17:453–455. - PMC - PubMed

LinkOut - more resources